Bioceltix (BCX.WA) Stock Price

Bioceltix Price

GPW·CLOSED
73.50
​
Market closed

Over the last 2 years Bioceltix grew revenue by 8.3% annually, reaching 10,800.00 PLN. For Bioceltix, the net margin of -21,747.7% is down versus -8,429.2% a few years ago. The consensus 12-month price target for Bioceltix is 132.75 PLN, about 80.6% above where the stock trades today. Of 6 analysts, 5 rate the stock a buy — an overall Buy consensus.

Bioceltix stock price

Access this data via the Eulerpool API

Bioceltix business model & stock analysis

Bioceltix SA engages in the research and development in the area of veterinary medicine. The company is headquartered in Wroclaw, Woj. Dolnoslaskie. The company went IPO on 2021-11-08. The firm deal with the development of candidates for veterinary medicinal products based on the immunomodulatory properties of mesenchymal stem cells used as the active substance of the drug. Entity's products are intended for the treatment of companion animals. The firm carry out research and development works, which enable clinical trials and full registration of medicinal products in the European Medicines Agency, as is the case with medicines and drugs administered to humans.

Frequently asked questions about Bioceltix

Analysts currently set an average price target of 132.75 PLN for the Bioceltix stock (median: 132.75 PLN), implying +80.6 % versus the latest price. The consensus is based on 6 analyst ratings.

6 analysts currently rate the Bioceltix stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Bioceltix to generate revenue of 21.50 M PLN and earnings per share of -4.51 PLN.

Converted at the current exchange rate, the Bioceltix share trades at 16.77 EUR (73.50 PLN).

The Bioceltix share (BCX.WA) is listed on 3 stock exchanges, including: Frankfurt (XI3.F).

The expected revenue of Bioceltix is 21.50 M PLN. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Bioceltix is -23.78 M PLN. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Bioceltix is currently -16.31. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Bioceltix stock.

The price-to-sales ratio (P/S) of Bioceltix is currently 18.04. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Bioceltix stock.

The Eulerpool Quality Score for Bioceltix is 2/10.

The ISIN of Bioceltix is PLBCLTX00019. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Bioceltix is A3C7NH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Bioceltix is BCX.WA. The ticker symbol is used to trade Bioceltix shares on the stock exchange.

Fair ValueTerminal
75.71 PLN
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Poland
Currency
PLN
Initial public offering
Nov 8, 2021
ISIN
PLBCLTX00019
Cusip
X0727H116
Market capitalization
406.46 M PLNSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-16.31
P/Ee 2027
10.50
P/Ee 2028
9.80
P/S
P/Se
18.04
EV/EBIT
—
P/B Ratio
5.55
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-20.60 %
Last updated Oct 10, 2026, 10:46 PM

Bioceltix Peer Group

Bioceltix Ticker

FRANKFURT · XI3.FWARSAW · BCX.WAWSE · BCX.WA

Bioceltix FIGI

BCX:PW · BBG013DQ9F61BCXPLN:EP · BBG013DQ9TX1BCXPLN:EZ · BBG013DQ9TZ9BCXPLN:XS · BBG013DQ9V02BCXPLN:X2 · BBG013DQ9V11BCXPLN:XH · BBG013DQ9V39BCXPLN:XF · BBG013DQ9V57BCXPLN:XE · BBG013DQ9V75BCXPLN:XJ · BBG013DQ9V84BCXPLN:XL · BBG013DQ9V93BCXPLN:XG · BBG013DQ9VB0BCXPLN:XO · BBG013DQ9VC9

All fundamentals and in-depth analysis of Bioceltix

Our stock analysis for Bioceltix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bioceltix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.